TSE:MBX - Microbix Biosystems Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started C$0.26 0.00 (0.00 %) (As of 07/23/2018 11:44 AM ET)Previous CloseC$0.26Today's RangeC$0.26 - C$0.2652-Week RangeC$0.25 - C$0.40Volume1,000 shsAverage Volume44,223 shsMarket CapitalizationC$27.10 millionP/E RatioN/ADividend YieldN/ABeta-1.95 Company ProfileEarnings HistoryInsider TradesHeadlinesSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Microbix Biosystems Inc. develops and commercializes biological and technology solutions for human health and wellbeing in North America, Europe, and internationally. It offers infectious disease antigens, including viral, bacterial, and parasitic products, which are used in various applications, such as immunodiagnostic assays comprising ELISA, chemiluminescent automated immunoassays, immunohistochemistry, immunofluorescence, latex agglutination, rapid tests, and flow cytometry; controls for diagnostic assays; basic and applied research in virology, microbiology, cell biology, immunology, and pathology; and for vaccine and antiviral research and development. The company also provides quality assessment products, including PROCEEDx Verification/Validation samples, which are research use only products for use in test system IQ/OQ/PQ, verification/validation, and training; PTDx proficiency testing products; and REDx Controls, which are designed to enhance the diagnostic quality outcome by early detection of the deviations from desired assay performance. Its development pipeline includes Kinlytic Urokinase for injection, a thrombolytic biologic drug used to treat blood clots; and LumiSort cell-sorting, a technology for sorting of somatic cells that could be used to enrich cell populations of interest, such as in sexing semen. Microbix Biosystems Inc. was founded in 1988 and is based in Mississauga, Canada. Receive MBX News and Ratings via Email Sign-up to receive the latest news and ratings for MBX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange TSE Industry Biotechnology Sub-IndustryN/A SectorMedical SymbolTSE:MBX CUSIPN/A Webmicrobix.com Phone+1-905-3618910 Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / CashN/A Book ValueN/A Price / BookN/A Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net Margins-3.26% Return on Equity-2.25% Return on Assets-1.40% Miscellaneous EmployeesN/A Outstanding Shares96,773,000Market CapC$27.10 Microbix Biosystems (TSE:MBX) Frequently Asked Questions What is Microbix Biosystems' stock symbol? Microbix Biosystems trades on the Toronto Stock Exchange (TSX) under the ticker symbol "MBX." When is Microbix Biosystems' next earnings date? Microbix Biosystems is scheduled to release their next quarterly earnings announcement on Monday, August, 13th 2018. View Earnings Estimates for Microbix Biosystems. What is the consensus analysts' recommendation for Microbix Biosystems? 0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Microbix Biosystems in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A." Who are some of Microbix Biosystems' key competitors? Some companies that are related to Microbix Biosystems include Emblem (EMMBF), Pfenex (PFNX), Oragenics (OGEN), Asterias Biotherapeutics (AST), Promis Neurosciences (PMN), Tissue Regenix Group (TRX), Covalon Technologies (COV), Matinas BioPharma (MTNB), Motif Bio (MTFB), Innovation Pharmaceuticals (IPIX), 4d Pharma (DDDD), Helix Biopharma (HBP), Ergomed (ERGO), Cardiome Pharma (COM) and GB Sciences (GBLX). Who are Microbix Biosystems' key executives? Microbix Biosystems' management team includes the folowing people: Mr. William J. Gastle, Founder & Exec. ChairmanMr. Cameron Groome, Pres, CEO & DirectorMr. James Currie, Chief Financial OfficerMr. Philip Casselli, Sr. VP of Sales, Bus. Devel. & MarketingMr. Vaughn C. Embro-Pantalony, Exec. Director Has Microbix Biosystems been receiving favorable news coverage? Media headlines about MBX stock have trended somewhat positive this week, Accern reports. Accern rates the sentiment of news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Microbix Biosystems earned a news impact score of 0.11 on Accern's scale. They also assigned news articles about the company an impact score of 45.88 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term. How do I buy shares of Microbix Biosystems? Shares of MBX and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab. What is Microbix Biosystems' stock price today? One share of MBX stock can currently be purchased for approximately C$0.26. How big of a company is Microbix Biosystems? Microbix Biosystems has a market capitalization of C$27.10 million. How can I contact Microbix Biosystems? Microbix Biosystems' mailing address is 265 Watline Ave, MISSISSAUGA, ON L4Z 1P3, Canada. The company can be reached via phone at +1-905-3618910. MarketBeat Community Rating for Microbix Biosystems (TSE MBX)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 37 (Vote Outperform)Underperform Votes: 35 (Vote Underperform)Total Votes: 72MarketBeat's community ratings are surveys of what our community members think about Microbix Biosystems and other stocks. Vote "Outperform" if you believe MBX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MBX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/23/2018 by MarketBeat.com StaffFeatured Article: How do investors use RSI to grade stocks?